Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.O)

ALNY.O on Nasdaq

52.32USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$52.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,175,002
52-wk High
$80.11
52-wk Low
$31.38

Latest Key Developments (Source: Significant Developments)

Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity
Wednesday, 8 Feb 2017 04:00pm EST 

Alnylam Pharmaceuticals Inc : Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity . Q4 revenue $17.5 million versus $7.6 million . Q4 revenue view $11 million -- Thomson Reuters I/B/E/S . Alnylam Pharmaceuticals Inc says expects to end 2017 with greater than $700 million in cash .Alnylam Pharmaceuticals Inc says also in early 2017, Alnylam plans to initiate ATLAS phase 3 program for fitusiran.  Full Article

ALNYLAM PRESENTS NEW DATA ON FITUSIRAN AT EAHAD
Thursday, 2 Feb 2017 11:45am EST 

Alnylam Pharmaceuticals Inc : ALNYLAM PHARMACEUTICALS INC - ANNOUNCED NEW RESULTS FROM AN EXPLORATORY ANALYSIS OF ITS PHASE 1 STUDY WITH FITUSIRAN . ALNYLAM PHARMA - NEW PHASE 1 RESULTS SHOWS EFFECTIVE BLEED MANAGEMENT WITH REPLACEMENT FACTOR AND BYPASSING AGENTS DURING FITUSIRAN ADMINISTRATION . ALNYLAM PHARMA- ANALYSIS OF BLEED MANAGEMENT DURING FITUSIRAN ADMINISTRATION SHOWED BREAKTHROUGH BLEEDS WERE EFFECTIVELY MANAGED . ALNYLAM PHARMACEUTICALS INC SAYS CONTINUE TO ADVANCE TOWARD START OF ATLAS PHASE 3 CLINICAL PROGRAM IN EARLY 2017 .ALNYLAM PHARMACEUTICALS INC - STABILITY STUDY RESULTS SUPPORT A GREATER THAN TWO YEAR PRODUCT SHELF-LIFE AT ROOM TEMPERATURE STORAGE CONDITIONS.  Full Article

Alnylam pharmaceuticals announces Sanofi Genzyme opt-in decision
Monday, 14 Nov 2016 08:00am EST 

Alnylam Pharmaceuticals Inc : Alnylam Pharmaceuticals announces Sanofi Genzyme opt-in decision for co-development and co-commercialization of fitusiran in hemophilia and rare bleeding disorders . Sanofi genzyme elects not to opt in for ALN-AS1 in acute hepatic porphyrias . Alnylam intends to commercialize ALN-AS1 globally upon product approval . Co, Sanofi Genzyme will co-develop and co-commercialize fitusiran in U.S., Canada, Western Europe . Alnylam pharma - Sanofi Genzyme will be required to make payments up to $75 million upon achievesanment of development, regulatory milestones for fitusiran .On track to initiate fitusiran Phase 3 program in early 2017.  Full Article

Alnylam completes enrollment in phase 3 study with revusiran
Monday, 8 Aug 2016 08:00am EDT 

Alnylam Pharmaceuticals Inc : Alnylam completes enrollment in endeavour phase 3 study with revusiran, an investigational rnai therapeutic for patients with hereditary attr amyloidosis with cardiomyopathy (hattr-cm) .Company expects to report data from study in early 2018..  Full Article

Alnylam Pharmaceuticals Q2 GAAP loss per share $1.05
Thursday, 4 Aug 2016 04:00pm EDT 

Alnylam Pharmaceuticals Inc : Q2 revenue $8.7 million versus I/B/E/S view $8.1 million . Alnylam Pharmaceuticals reports second quarter 2016 financial results and highlights recent period progress . Q2 GAAP loss per share $1.05 including items . Q2 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S .Alnylam Pharmaceuticals Inc says remains on track to end 2016 with greater than $1.0 billion in cash.  Full Article

Alnylam starts early-stage trial for ALN-TTRsc02
Thursday, 9 Jun 2016 08:00am EDT 

Alnylam Initiates Phase 1 Clinical Trial For Aln : Expects to present initial clinical results in late 2016 and to initiate a phase 3 study in 2017 .TTRsc02, an investigational RNAi therapeutic for the treatment of TTR-mediated amyloidosis.  Full Article

Bioxcel Corp says begins collaboration with Alnylam to discover novel RNAi therapeutic products
Tuesday, 24 May 2016 12:30pm EDT 

BioXcel Corporation : Begins strategic collaboration with Alnylam to discover novel RNAi therapeutic products;financial terms of agreement were not disclosed .Under terms of agreement, BioXcel will be eligible to receive upfront and development milestone related payments from Alnylam.  Full Article

Alnylam Pharmaceuticals initiates phase 1 Open Label Extension (OLE) Study with ALN-AT3
Thursday, 8 Oct 2015 04:00pm EDT 

Alnylam Pharmaceuticals:Initiated a Phase 1 open-label extension (OLE) study with ALN-AT3, a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders.Says the Phase 1 OLE study will evaluate the long-term safety and efficacy of ALN-AT3 and provide people with hemophilia enrolled in the Phase 1 study the opportunity for continued dosing.Company plans to report clinical data from the Phase 1 OLE study at least once per year, beginning in 2016.  Full Article

Alnylam Pharmaceuticals Inc and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic
Monday, 28 Sep 2015 08:00am EDT 

Alnylam Pharmaceuticals Inc:Alnylam and collaborators report first-ever evidence that patisiran reduces pathogenic, misfolded transthyretin monomers.Patisiran achieves an approximately 90% reduction in misfolded non-native conformations of ttr as measured in serum.  Full Article

Alnylam Pharmaceuticals reports positive initial clinical results for ALN-AS1
Tuesday, 15 Sep 2015 07:00am EDT 

Alnylam Pharmaceuticals Inc:Announces initial positive results from its ongoing Phase 1 clinical trial with ALN-AS1, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias.  Full Article

More From Around the Web

BRIEF-Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran

* Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran, an investigational rnai therapeutic for the treatment of acute hepatic porphyrias